All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
S14 Ep48: PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO
OncLive® On Air
26 minutes
1 week ago
S14 Ep48: PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO
Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.
OncLive® On Air
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
